{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:47:37Z","timestamp":1779205657994,"version":"3.51.4"},"reference-count":143,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bpsc.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:42:08Z","timestamp":1594035728000},"page":"646-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Cannabinoid CB1 Receptor in Schizophrenia"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-5226","authenticated-orcid":false,"given":"Faith","family":"Borgan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-2264","authenticated-orcid":false,"given":"Michelle","family":"Kokkinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Howes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsc.2020.06.018_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-244X-12-64","article-title":"Cognitive deficits in schizophrenia: An updated metanalysis of the scientific evidence","volume":"12","author":"Fioravanti","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014An overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(98)07507-2","article-title":"Multiple-informant ranking of the disabling effects of different health conditions in 14 countries: WHO\/NIH Joint Project CAR Study Group","volume":"354","author":"Ust\u00fcn","year":"1999","journal-title":"Lancet (London)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: Findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib5","series-title":"The Maudsley Prescribing Guidelines in Psychiatry","year":"2012"},{"key":"10.1016\/j.bpsc.2020.06.018_bib6","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib7","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-013-2994-z","article-title":"Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: A randomized comparison of haloperidol, olanzapine, and risperidone","volume":"227","author":"Ayesa-Arriola","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jamapsychiatry.2019.0970","article-title":"Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis","volume":"76","author":"Minichino","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/0929867306666220401124036","article-title":"Pharmacology of cannabinoid receptor ligands","volume":"6","author":"Pertwee","year":"1999","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bpsc.2020.06.018_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nchembio0309-131","article-title":"Building a new conceptual framework for receptor heteromers","volume":"5","author":"Ferr\u00e9","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib17","doi-asserted-by":"crossref","first-page":"20851","DOI":"10.1074\/jbc.M111.335273","article-title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain","volume":"287","author":"Call\u00e9n","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1124\/mol.104.006882","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: A mechanism for receptor cross-talk?","volume":"67","author":"Kearn","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002194","article-title":"Cognitive impairment induced by delta9- tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors","volume":"13","author":"Vi\u00f1als","year":"2015","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1254\/jphs.08244FP","article-title":"\u03bc-Opioid Receptor Forms a Functional Heterodimer With Cannabinoid CB1 Receptor: Electrophysiological and FRET Assay Analysis","volume":"108","author":"Hojo","year":"2008","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib21","first-page":"1088","article-title":"Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer","volume":"8","author":"Navarro","year":"2008","journal-title":"SciWorldJ"},{"key":"10.1016\/j.bpsc.2020.06.018_bib22","series-title":"Essential Cell Biology","author":"Alberts","year":"2009"},{"key":"10.1016\/j.bpsc.2020.06.018_bib23","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/35069076","article-title":"Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses: Marijuana affects brain function primarily by activating the G-protein-coupled cannabinoid receptor-1 (CB1)","volume":"401","author":"Wilson","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bpsc.2020.06.018_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pnpbp.2014.01.019","article-title":"Release of endogenous cannabinoids from ventral tegmental area dopamine neurons and the modulation of synaptic processes","volume":"52","author":"Wang","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-Tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(01)00372-5","article-title":"Presynaptic specificity of endocannabinoid signaling in the hippocampus","volume":"31","author":"Wilson","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.bpsc.2020.06.018_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00019.2008","article-title":"Endocannabinoid-mediated control of synaptic transmission","volume":"89","author":"Kano","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bpsc.2020.06.018_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Di Marzo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bpsc.2020.06.018_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Di Marzo","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bpsc.2020.06.018_bib31","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1523\/JNEUROSCI.1844-14.2014","article-title":"Enhanced endocannabinoid-mediated modulation of rostromedial tegmental nucleus drive onto dopamine neurons in Sardinian alcohol-preferring rats","volume":"34","author":"Melis","year":"2014","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuropharm.2013.12.007","article-title":"Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the substantia nigra pars compacta","volume":"79","author":"Freestone","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib33","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1523\/JNEUROSCI.0448-07.2007","article-title":"Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum","volume":"27","author":"Uchigashima","year":"2007","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/bph.12969","article-title":"The endocannabinoid system regulates synaptic transmission in nucleus accumbens by increasing DAGL-\u03b1 expression following short-term morphine withdrawal","volume":"173","author":"Wang","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cercor\/bhj133","article-title":"Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons","volume":"17","author":"Fortin","year":"2006","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.bpsc.2020.06.018_bib36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/BF02245916","article-title":"Delta 9-Tetrahydrocannablnol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis","volume":"102","author":"Chen","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00001756-199702100-00014","article-title":"Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra","volume":"8","author":"French","year":"1997","journal-title":"NeuroReport"},{"key":"10.1016\/j.bpsc.2020.06.018_bib38","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/schbul\/sbx180","article-title":"Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis","volume":"44","author":"McCutcheon","year":"2018","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: From biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuropharm.2007.07.003","article-title":"CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2","volume":"54","author":"N\u00e9meth","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib41","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/cercor\/bhx117","article-title":"Chronic inflammatory pain impairs mGluR5-mediated depolarization-induced suppression of excitation in the anterior cingulate cortex","volume":"28","author":"Guo","year":"2018","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.bpsc.2020.06.018_bib42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpsyt.2013.00151","article-title":"Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis","volume":"4","author":"Merritt","year":"2013","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib45","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib46","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib47","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2215-0366(16)30188-2","article-title":"Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","article-title":"High-potency cannabis and the risk of psychosis","volume":"195","author":"Di Forti","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib50","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","article-title":"GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia","volume":"21","author":"Pasman","year":"2018","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.drugalcdep.2018.05.024","article-title":"Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence","volume":"190","author":"Hiemstra","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.bpsc.2020.06.018_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.09.022","article-title":"Short communication: Genetic association between schizophrenia and cannabis use","volume":"171","author":"Verweij","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.bpsc.2020.06.018_bib53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1017\/S0033291719003362","article-title":"No evidence of associations between\u00a0genetic liability for schizophrenia and development of cannabis use disorder","volume":"51","author":"Hjorth\u00f8j","year":"2021","journal-title":"Psychol Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib54","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/mp.2016.252","article-title":"Cannabis use and risk of schizophrenia: A Mendelian randomization study","volume":"23","author":"Vaucher","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib55","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1017\/S0033291716003172","article-title":"Assessing causality in associations between cannabis use and schizophrenia risk: A two-sample Mendelian randomization study","volume":"47","author":"Gage","year":"2017","journal-title":"Psychol Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1017\/S0033291717001209","article-title":"Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not","volume":"48","author":"Aas","year":"2018","journal-title":"Psychol Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1471-4159.1999.0730493.x","article-title":"Internalization and recycling of the CB1 cannabinoid receptor","volume":"73","author":"Hsieh","year":"1999","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pharmthera.2007.10.003","article-title":"Role of receptor internalization in opioid tolerance and dependence","volume":"117","author":"Koch","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bpsc.2020.06.018_bib61","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib62","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1017\/S0033291709005522","article-title":"The acute effects of synthetic intravenous \u03949-tetrahydrocannabinol on psychosis, mood and cognitive functioning","volume":"39","author":"Morrison","year":"2009","journal-title":"Psychol Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib63","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1162\/jocn_a_00156","article-title":"Effects of \u03949-tetrahydrocannabinol administration on human encoding and recall memory function: A pharmacological fMRI study","volume":"24","author":"Bossong","year":"2012","journal-title":"J\u00a0Cogn Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib64","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib67","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib68","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.bpsc.2020.06.018_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-020-00110-7","article-title":"Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis","volume":"6","author":"Dickens","year":"2020","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.bpsc.2020.06.018_bib70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.bpsc.2020.06.018_bib71","first-page":"60","article-title":"Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis","volume":"1","author":"D\u2019Souza","year":"2016","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.bpsc.2020.06.018_bib72","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1523\/JNEUROSCI.21-07-02425.2001","article-title":"Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons","volume":"21","author":"Coutts","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib73","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib74","doi-asserted-by":"crossref","first-page":"109666","DOI":"10.1016\/j.pnpbp.2019.109666","article-title":"Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia","volume":"95","author":"Osborne","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2016.09.020","article-title":"Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia","volume":"633","author":"Sz\u0171cs","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bpsc.2020.06.018_bib76","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/15622975.2013.841993","article-title":"Dominant negative DISC1 mutant mice display specific social behaviour deficits and aberration in BDNF and cannabinoid receptor expression","volume":"15","author":"Kaminitz","year":"2014","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib77","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/hipo.20537","article-title":"Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB1 and CB2 cannabinoid receptors of neonatal rats","volume":"19","author":"Su\u00e1rez","year":"2009","journal-title":"Hippocampus"},{"key":"10.1016\/j.bpsc.2020.06.018_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2014.05.004","article-title":"Prenatal poly I:C age-dependently alters cannabinoid type 1 receptors in offspring: A longitudinal small animal PET study using [18F]MK-9470","volume":"257","author":"Verdurand","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nbd.2015.06.006","article-title":"Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory","volume":"82","author":"Ballinger","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bpsc.2020.06.018_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.brainres.2010.04.031","article-title":"The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling","volume":"1343","author":"Robinson","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pbb.2017.06.010","article-title":"\u03949-Tetrahydrocannabinol (\u03949-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice","volume":"159","author":"Rodr\u00edguez","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.bpsc.2020.06.018_bib82","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0269881119857205","article-title":"Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia","volume":"33","author":"Muguruza","year":"2019","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib83","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib84","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib85","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib86","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: Effect of antipsychotic treatment","volume":"206","author":"Urig\u00fcen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.bpsc.2020.06.018_bib88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12264-007-0051-9","article-title":"No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia","volume":"23","author":"Deng","year":"2007","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib91","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp Brain Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib92","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"NeuroImage"},{"key":"10.1016\/j.bpsc.2020.06.018_bib93","series-title":"Experimental Design and Practical Data Analysis in Positron Emission Tomography","author":"Turkheimer","year":"2014"},{"key":"10.1016\/j.bpsc.2020.06.018_bib94","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.neuroimage.2010.04.034","article-title":"Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR","volume":"52","author":"Wong","year":"2010","journal-title":"NeuroImage"},{"key":"10.1016\/j.bpsc.2020.06.018_bib95","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia","volume":"79","author":"Ranganathan","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib96","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamapsychiatry.2019.1427","article-title":"In\u00a0vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis","volume":"76","author":"Borgan","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib97","article-title":"The neural and molecular basis of working memory function in psychosis: A multimodal PET-fMRI study","author":"Borgan","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib98","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.neuroimage.2018.10.013","article-title":"Sex difference in brain CB1 receptor availability in man","volume":"184","author":"Laurikainen","year":"2019","journal-title":"NeuroImage"},{"key":"10.1016\/j.bpsc.2020.06.018_bib99","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbr.2009.05.013","article-title":"Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats","volume":"203","author":"Reich","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.60.6.565","article-title":"Sex differences in the risk of schizophrenia: Evidence from meta-analysis","volume":"60","author":"Aleman","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.npp.1301402","article-title":"The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain","volume":"33","author":"Yasuno","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib102","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00210-005-1074-2","article-title":"Clozapine decreases [3H]CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens","volume":"371","author":"Sundram","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib103","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.neuropharm.2008.07.026","article-title":"Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in\u00a0vivo pharmacology in rats","volume":"55","author":"Wiley","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib104","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0022-3565(25)10481-3","article-title":"Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-\u03949-THC-DMH","volume":"263","author":"Thomas","year":"1992","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bpsc.2020.06.018_bib105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/schbul\/sbaa038","article-title":"Altered signaling in CB1R-5-HT2AR heteromers in olfactory neuroepithelium cells of schizophrenia patients is modulated by cannabis use","volume":"46","author":"Guinart","year":"2020","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib106","doi-asserted-by":"crossref","first-page":"a012229","DOI":"10.1101\/cshperspect.a012229","article-title":"A\u00a0brain on cannabinoids: The role of dopamine release in reward seeking","volume":"2","author":"Oleson","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib107","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1471-4159.2006.03880.x","article-title":"Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats","volume":"98","author":"Solinas","year":"2006","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1471-4159.1998.70020671.x","article-title":"Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission","volume":"70","author":"Hampson","year":"1998","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib109","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neuropharm.2013.11.018","article-title":"Pharmacological activation of CB1 receptor modulates long term potentiation by interfering with protein synthesis","volume":"79","author":"Navakkode","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-5793(00)01425-3","article-title":"Anandamide induces apoptosis of PC-12 cells: Involvement of superoxide and caspase-3","volume":"472","author":"Sarker","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bpsc.2020.06.018_bib112","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.107.131607","article-title":"Cannabinoids inhibit network-driven synapse loss between hippocampal neurons in culture","volume":"325","author":"Kim","year":"2008","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.bpsc.2020.06.018_bib113","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep.20667","article-title":"Anandamide induces necrosis in primary hepatic stellate cells","volume":"41","author":"Siegmund","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1176\/appi.ajp.161.1.109","article-title":"Apoptotic proteins in the temporal cortex in schizophrenia: High Bax\/Bcl-2 ratio without caspase-3 activation","volume":"161","author":"Jarskog","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41467-019-14122-0","article-title":"Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats","volume":"11","author":"Onwordi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bpsc.2020.06.018_bib116","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/oxfordjournals.schbul.a007038","article-title":"The stress cascade and schizophrenia: Etiology and onset","volume":"29","author":"Corcoran","year":"2003","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib117","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/npp.2012.100","article-title":"Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans","volume":"37","author":"Dlugos","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bpsc.2020.06.018_bib118","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2009.04.048","article-title":"Chronic stress differentially regulates cannabinoid CB1 receptor binding in distinct hippocampal subfields","volume":"614","author":"Hill","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","article-title":"The role of genes, stress, and dopamine in the development of schizophrenia","volume":"81","author":"Howes","year":"2017","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib120","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1242\/dev.125.16.3179","article-title":"Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development","volume":"125","author":"Berrendero","year":"1998","journal-title":"Development"},{"key":"10.1016\/j.bpsc.2020.06.018_bib121","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1098\/rstb.2011.0385","article-title":"Endocannabinoids via CB1 receptors act as neurogenic niche cues during cortical development","volume":"367","author":"D\u00edaz-Alonso","year":"2012","journal-title":"Philos Trans R Soc London B Biol Sci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib122","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fnana.2018.00104","article-title":"Neural progenitor cell terminology","volume":"12","author":"Mart\u00ednez-Cerde\u00f1o","year":"2018","journal-title":"Front Neuroanat"},{"key":"10.1016\/j.bpsc.2020.06.018_bib123","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1523\/JNEUROSCI.1683-10.2010","article-title":"Development\/plasticity\/repair brain-derived neurotrophic factor controls cannabinoid CB1 receptor function in the striatum","volume":"30","author":"De Chiara","year":"2010","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib124","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamapsychiatry.2019.0076","article-title":"Association of prenatal cannabis exposure with psychosis proneness among children in the Adolescent Brain Cognitive Development (ABCD) Study","volume":"76","author":"Fine","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1515\/jpm-2019-0422","article-title":"Maternal smoking and cannabis use during pregnancy and infant outcomes","volume":"48","author":"Sturrock","year":"2020","journal-title":"J\u00a0Perinat Med"},{"key":"10.1016\/j.bpsc.2020.06.018_bib126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: Version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bpsc.2020.06.018_bib127","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib128","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.bcp.2004.07.034","article-title":"The GABA-glutamate connection in schizophrenia: Which is the proximate cause?","volume":"68","author":"Coyle","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib129","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","article-title":"Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial","volume":"134","author":"Boggs","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib131","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib132","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/BF03262000","article-title":"Reasons for and time to discontinuation of rimonabant therapy: A modified prescription-event monitoring study","volume":"35","author":"Willemen","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpsc.2020.06.018_bib133","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.3390\/ijms20235874","article-title":"Allosteric modulation of cannabinoid receptor 1\u2014Current challenges and future opportunities","volume":"20","author":"Hryhorowicz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bpsc.2020.06.018_bib134","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/can.2015.0005","article-title":"Allosteric modulators of the CB1 cannabinoid receptor: A structural update review","volume":"1","author":"Morales","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.bpsc.2020.06.018_bib135","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib136","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220025","article-title":"Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9tetrahydrocannabinol: An in silico study","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bpsc.2020.06.018_bib138","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: A randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bpsc.2020.06.018_bib139","doi-asserted-by":"crossref","first-page":"pyw068","DOI":"10.1093\/ijnp\/pyw068","article-title":"The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability","volume":"19","author":"Gueye","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib140","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1016\/j.bmc.2017.10.015","article-title":"Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor","volume":"25","author":"Bertini","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bpsc.2020.06.018_bib141","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1476-5381.2009.00515.x","article-title":"Evidence that the plant cannabinoid cannabigerol is a highly potent \u03b12-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist","volume":"159","author":"Cascio","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib142","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bjp.0706414","article-title":"Evidence that the plant cannabinoid \u03949- tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist","volume":"146","author":"Thomas","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bpsc.2020.06.018_bib143","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced Cortical Cannabinoid 1 Receptor Messenger RNA and Protein Expression in Schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bpsc.2020.06.018_bib144","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J\u00a0Neural Transm"}],"container-title":["Biological Psychiatry: Cognitive Neuroscience and Neuroimaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451902220301737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451902220301737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:16:34Z","timestamp":1762521394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451902220301737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":143,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2451902220301737"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsc.2020.06.018","relation":{},"ISSN":["2451-9022"],"issn-type":[{"value":"2451-9022","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cannabinoid CB1 Receptor in Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry: Cognitive Neuroscience and Neuroimaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsc.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}